Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 10/20 | 0.45 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15057989 | 0.96 | PTGER1 (0.47) | PTGER1NLRP3 | |
| SCHEMBL15056799 | 0.90 | PTGER1 (0.47) | PTGER1KMO | |
| SCHEMBL15057147 | 0.89 | MAPT (0.38) | PTGER1MAOAMAOB | |
| SCHEMBL15057912 | 0.86 | NLRP3 (0.53) | NLRP3MAOAMAOBKMO | |
| SCHEMBL15057058 | 0.86 | PTGER1 (0.48) | PTGER1KMO | |
| SCHEMBL15058233 | 0.86 | PTGER1 (0.39) | PTGER1NLRP3 | |
| SCHEMBL15076167 | 0.85 | PTGER1 (0.52) | PTGER1 | |
| SCHEMBL15058086 | 0.85 | PTGER1 (0.49) | PTGER1 | |
| SCHEMBL15058170 | 0.84 | NLRP3 (0.44) | PTGER1NLRP3MAOAMAOB | |
| SCHEMBL15058191 | 0.84 | PTGER1 (0.55) | PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210221810-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20210221810-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. | 2021-07-22 | — | — | US | disclosed |
| US-10988474-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988474-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3424904-B1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3424904-B1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20200216440-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200216440-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2020-07-09 | — | — | US | disclosed |
| US-10392382-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10392382-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20170137423-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2017-05-18 | — | — | US | disclosed |
| US-9567328-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567328-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567328-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| EP-2794561-A2 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20130184463-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184463-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184463-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013096496-A2 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096496-A2 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216440-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, PTGER2 | PTGER1 1/4885NLRP3 1299/4885GABRA1 598/4885 |
| US-20210221810-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, PTGER2 | PTGER1 1/4885NLRP3 1299/4885GABRA1 598/4885 |
| US-10392382-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | PTGER1, PTGER4, PTGER2 | PTGER1 1/4885NLRP3 1299/4885GABRA1 598/4885 |
| US-10988474-B2 | Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response | PTGER1, PTGER4, PTGER2 | PTGER1 1/4885NLRP3 1299/4885GABRA1 598/4885 |
| US-20130184463-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, PTGER2 | PTGER1 1/4885NLRP3 1299/4885GABRA1 598/4885 |
| US-20170137423-A1 | COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, PTGER2 | PTGER1 1/4885NLRP3 1299/4885GABRA1 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.